IL218565A0 - Polymorphic and pseudopolymorphic forms of a pharmaceutical compound - Google Patents
Polymorphic and pseudopolymorphic forms of a pharmaceutical compoundInfo
- Publication number
- IL218565A0 IL218565A0 IL218565A IL21856512A IL218565A0 IL 218565 A0 IL218565 A0 IL 218565A0 IL 218565 A IL218565 A IL 218565A IL 21856512 A IL21856512 A IL 21856512A IL 218565 A0 IL218565 A0 IL 218565A0
- Authority
- IL
- Israel
- Prior art keywords
- polymorphic
- pharmaceutical compound
- pseudopolymorphic forms
- pseudopolymorphic
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0904864A FR2951171A1 (en) | 2009-10-09 | 2009-10-09 | NOVEL SODIUM SALT OF A CRYSTALLIZED ENANTIOMER AZABICYCLIC COMPOUND AND NOVEL POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS AND THEIR PREPARATION |
US26366309P | 2009-11-23 | 2009-11-23 | |
PCT/EP2010/065147 WO2011042560A1 (en) | 2009-10-09 | 2010-10-08 | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound |
Publications (1)
Publication Number | Publication Date |
---|---|
IL218565A0 true IL218565A0 (en) | 2012-05-31 |
Family
ID=42154208
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL218565A IL218565A0 (en) | 2009-10-09 | 2012-03-08 | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound |
IL239663A IL239663A0 (en) | 2009-10-09 | 2015-06-25 | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound |
IL259296A IL259296B (en) | 2009-10-09 | 2018-05-13 | Sodium salt of (1r,2s,5r)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL239663A IL239663A0 (en) | 2009-10-09 | 2015-06-25 | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound |
IL259296A IL259296B (en) | 2009-10-09 | 2018-05-13 | Sodium salt of (1r,2s,5r)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
Country Status (22)
Country | Link |
---|---|
US (5) | US8471025B2 (en) |
EP (3) | EP3269717B9 (en) |
JP (4) | JP6072540B2 (en) |
KR (4) | KR20200010586A (en) |
CN (3) | CN109824668A (en) |
AU (1) | AU2010304974B2 (en) |
BR (2) | BR122019021689B8 (en) |
CA (1) | CA2716914C (en) |
CY (1) | CY1121583T1 (en) |
DK (1) | DK3269717T5 (en) |
ES (2) | ES2721228T5 (en) |
FI (1) | FI3269717T4 (en) |
FR (1) | FR2951171A1 (en) |
HU (1) | HUE043086T2 (en) |
IL (3) | IL218565A0 (en) |
MX (1) | MX2012003730A (en) |
MY (1) | MY174776A (en) |
PL (1) | PL3269717T5 (en) |
PT (1) | PT3269717T (en) |
RU (1) | RU2727509C2 (en) |
SI (1) | SI3269717T2 (en) |
WO (1) | WO2011042560A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247400B2 (en) * | 2009-02-23 | 2012-08-21 | Dedhiya Mahendra G | Cephem compounds useful for the treatment of bacterial infections |
US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
CA2822758C (en) * | 2010-12-22 | 2018-03-20 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivative and process for preparing the same |
JP6023800B2 (en) * | 2011-06-17 | 2016-11-09 | アストラゼネカ アクチボラグ | Process for producing a heterocyclic compound containing trans-7-oxo-6- (sulfooxy) -1,6-diazabicyclo [3,2,1] octane-2-carboxamide and a salt thereof |
MX338610B (en) * | 2011-07-26 | 2016-04-25 | Wockhardt Ltd | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor. |
MX348974B (en) * | 2011-08-27 | 2017-07-04 | Wockhardt Ltd | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections. |
US8969567B2 (en) | 2011-09-13 | 2015-03-03 | Wockhardt Ltd. | Nitrogen containing compounds and their use |
MX349827B (en) * | 2011-09-13 | 2017-08-14 | Wockhardt Ltd | Nitrogen containing compounds and their use. |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
JP2015512419A (en) | 2012-03-30 | 2015-04-27 | キュービスト ファーマシューティカルズ, インコーポレイテッド | Isooxazole β-lactamase inhibitor |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US8962843B2 (en) * | 2012-03-30 | 2015-02-24 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
AR090539A1 (en) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | INHIBITING COMPOUNDS OF B LACTAMASA |
TWI565707B (en) | 2012-05-30 | 2017-01-11 | 明治製菓藥業股份有限公司 | Novel β-lactamase inhibitor and method for producing same |
JP6285970B2 (en) * | 2013-03-08 | 2018-02-28 | ウォックハート リミテッド | (2S, 5R) -7-oxo-6-sulfooxy-2-[((3R) -pyrrolidine-3-carbonyl) -hydrazinocarbonyl] -1,6-diaza-bicyclo [3.2.1] octane Process for preparation |
WO2014135930A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
WO2014152996A1 (en) | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
JP6453222B2 (en) | 2013-09-24 | 2019-01-16 | Meiji Seikaファルマ株式会社 | Preparation of diazabicyclooctane derivatives and their intermediates |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
AR097971A1 (en) | 2013-10-08 | 2016-04-20 | Meiji Seika Pharma Co Ltd | CRYSTAL FORMS OF DIAZABICICLOOCTAN DERIVATIVE AND THE PRODUCTION PROCESS OF THEM |
CN106029068A (en) * | 2014-02-20 | 2016-10-12 | 沃克哈特有限公司 | Pharmaceutical combinations comprising antibacterial agents |
WO2016066631A1 (en) | 2014-10-28 | 2016-05-06 | Sandoz Ag | Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution |
WO2016081452A1 (en) | 2014-11-17 | 2016-05-26 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
BR112017010445B8 (en) | 2014-12-05 | 2024-02-27 | Meiji Seika Pharma Co Ltd | Production process of diazabicyclo-octane derivative crystals and stable lyophilized preparation |
EP3334734B1 (en) | 2015-08-10 | 2020-01-01 | Sandoz AG | Form c of avibactam sodium |
CN107325096B (en) * | 2016-04-29 | 2020-11-03 | 正大天晴药业集团股份有限公司 | Crystallization of avibactam monosodium salt |
CA3034470A1 (en) | 2016-08-26 | 2018-03-01 | Sandoz Ag | Avibactam free acid |
WO2018053215A1 (en) | 2016-09-16 | 2018-03-22 | Entasis Therapeutics Limited | Beta-lactamase inhibitor compounds |
CN107880042A (en) * | 2016-09-30 | 2018-04-06 | 上海复星星泰医药科技有限公司 | The preparation method of AVM hereinafter Batan sodium and its midbody compound |
CA3052100A1 (en) | 2017-02-08 | 2018-08-16 | Sandoz Ag | Process for the preparation of crystalline form c of avibactam sodium |
SG11201909443YA (en) | 2017-05-08 | 2019-11-28 | Entasis Therapeutics Inc | Compounds and methods for treating bacterial infections |
EP3687504A1 (en) * | 2017-09-27 | 2020-08-05 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same |
CN111448195A (en) * | 2017-09-27 | 2020-07-24 | 费多拉制药公司 | Crystal forms of diazabicyclooctane derivatives and methods for their production |
JP7200235B2 (en) * | 2017-09-27 | 2023-01-06 | Meiji Seikaファルマ株式会社 | Dosage form of diazabicyclooctane derivative and production method thereof |
CN107501265B (en) * | 2017-10-09 | 2019-05-28 | 台州职业技术学院 | A kind of 7- oxo-diazabicylo [3,2,1] octane derivatives compound and its preparation method and application |
CN109678856B (en) | 2017-10-18 | 2020-09-25 | 新发药业有限公司 | Preparation method of avibactam intermediate |
CN107827886B (en) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | Refining preparation process of high-purity abamectin |
CN109956941B (en) | 2017-12-25 | 2020-08-04 | 新发药业有限公司 | Simple preparation method of abamectin |
CN107936017A (en) * | 2018-01-12 | 2018-04-20 | 上海龙翔生物医药开发有限公司 | A kind of method that crystal form A or crystal form D AVM hereinafter Batan products are prepared by crystallization |
CN107935945A (en) * | 2018-01-12 | 2018-04-20 | 上海龙翔生物医药开发有限公司 | A kind of method that crystal form A or crystal form D AVM hereinafter Batan products are prepared by reaction |
CN110078728B (en) * | 2019-05-23 | 2020-10-23 | 江西富祥药业股份有限公司 | Abamebactam intermediate, preparation method and application thereof |
CN113105455B (en) * | 2020-01-10 | 2024-05-17 | 四川科伦药物研究院有限公司 | Preparation method of crystal form B avibactam sodium |
CN111689964A (en) * | 2020-07-21 | 2020-09-22 | 海南海灵化学制药有限公司 | Stable crystal form of abamectin sodium and preparation method thereof |
CN114249729A (en) * | 2020-09-23 | 2022-03-29 | 四川科伦药物研究院有限公司 | Method for preparing crystal form B avibactam sodium through reaction crystallization |
CN115677697A (en) * | 2022-09-19 | 2023-02-03 | 瑞阳制药股份有限公司 | Crystallization method of B crystal form abamectin sodium with adjustable particle size and good fluidity |
KR20240041506A (en) * | 2022-09-23 | 2024-04-01 | 주식회사 경보제약 | Stable monohydrate form of avibactam sodium and manufacturaing method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2895630B2 (en) * | 1993-12-29 | 1999-05-24 | フアイザー・インコーポレイテツド | Diazabicyclo neurokinin antagonist |
TW473479B (en) | 1997-12-19 | 2002-01-21 | Takeda Chemical Industries Ltd | Phosphonocephem derivatives, their production and use |
CZ20022332A3 (en) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sample assembly |
FR2812635B1 (en) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS |
DK1310502T3 (en) * | 2000-08-10 | 2009-09-07 | Takeda Pharmaceutical | Phosphonocephem compound |
FR2835186B1 (en) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
EP2068958B1 (en) * | 2006-09-28 | 2016-10-19 | Cook Medical Technologies LLC | Medical device including an anesthetic and method of preparation thereof |
FR2921060B1 (en) | 2007-09-14 | 2012-06-15 | Novexel | NOVEL PROCESS FOR PREPARING DISUBSIDED PIPERIDINE AND NOVEL INTERMEDIATES |
EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
MX2012003411A (en) * | 2009-09-21 | 2012-04-30 | Forest Lab Holdings Ltd | Compositions and methods for treating bacterial infections using ceftaroline. |
-
2009
- 2009-10-09 FR FR0904864A patent/FR2951171A1/en active Pending
-
2010
- 2010-10-08 CN CN201910137306.4A patent/CN109824668A/en active Pending
- 2010-10-08 BR BR122019021689A patent/BR122019021689B8/en active IP Right Grant
- 2010-10-08 EP EP17182561.5A patent/EP3269717B9/en active Active
- 2010-10-08 EP EP19151839.8A patent/EP3505518A1/en active Pending
- 2010-10-08 MX MX2012003730A patent/MX2012003730A/en active IP Right Grant
- 2010-10-08 AU AU2010304974A patent/AU2010304974B2/en active Active
- 2010-10-08 CN CN201080045819.XA patent/CN102834395B/en active Active
- 2010-10-08 RU RU2015137928A patent/RU2727509C2/en active
- 2010-10-08 WO PCT/EP2010/065147 patent/WO2011042560A1/en active Application Filing
- 2010-10-08 ES ES17182561T patent/ES2721228T5/en active Active
- 2010-10-08 CA CA2716914A patent/CA2716914C/en active Active
- 2010-10-08 MY MYPI2012001576A patent/MY174776A/en unknown
- 2010-10-08 SI SI201031873T patent/SI3269717T2/en unknown
- 2010-10-08 FI FIEP17182561.5T patent/FI3269717T4/en active
- 2010-10-08 KR KR1020207001713A patent/KR20200010586A/en not_active IP Right Cessation
- 2010-10-08 PT PT17182561T patent/PT3269717T/en unknown
- 2010-10-08 CN CN201410836227.XA patent/CN104592229A/en active Pending
- 2010-10-08 KR KR1020127009004A patent/KR101817811B1/en active IP Right Grant
- 2010-10-08 KR KR1020177034526A patent/KR20170134791A/en not_active Application Discontinuation
- 2010-10-08 US US12/900,567 patent/US8471025B2/en active Active
- 2010-10-08 ES ES10762934.7T patent/ES2645110T3/en active Active
- 2010-10-08 DK DK17182561.5T patent/DK3269717T5/en active
- 2010-10-08 BR BR112012007976-0A patent/BR112012007976B1/en active IP Right Grant
- 2010-10-08 JP JP2012532627A patent/JP6072540B2/en active Active
- 2010-10-08 HU HUE17182561A patent/HUE043086T2/en unknown
- 2010-10-08 PL PL17182561.5T patent/PL3269717T5/en unknown
- 2010-10-08 EP EP10762934.7A patent/EP2486038B1/en active Active
- 2010-10-08 KR KR1020187016242A patent/KR20180067717A/en active Search and Examination
-
2012
- 2012-03-08 IL IL218565A patent/IL218565A0/en unknown
-
2013
- 2013-05-24 US US13/901,724 patent/US8835455B2/en active Active
-
2014
- 2014-08-07 US US14/454,141 patent/US9062053B2/en active Active
-
2015
- 2015-05-13 US US14/711,162 patent/US9580424B2/en active Active
- 2015-06-25 IL IL239663A patent/IL239663A0/en unknown
- 2015-10-09 JP JP2015201555A patent/JP6197170B2/en active Active
-
2017
- 2017-01-13 US US15/405,409 patent/US20170210742A1/en not_active Abandoned
- 2017-04-14 JP JP2017080380A patent/JP6321853B2/en active Active
-
2018
- 2018-04-04 JP JP2018072510A patent/JP6630391B2/en active Active
- 2018-05-13 IL IL259296A patent/IL259296B/en unknown
-
2019
- 2019-04-25 CY CY20191100453T patent/CY1121583T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL239663A0 (en) | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | |
HK1175470A1 (en) | Aryl and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | |
PT2459176T (en) | Crystallization method and bioavailability | |
EP2519926A4 (en) | Facilitating sponsorship of game-play-based achievements | |
GB2474075B (en) | Display assembly having different types of display | |
AP3169A (en) | A method of improved positioning | |
AP3659A (en) | A novel formulation of meloxicam | |
GB0917305D0 (en) | System and method of calibrating a system | |
GB0922589D0 (en) | Pharmaceutical compounds | |
EP2400848A4 (en) | Crystallization of pharmaceutical compounds | |
GB2469543B (en) | Construction of geometrical shapes | |
EP2273994A4 (en) | Solid state forms of a pharmaceutical | |
PL2301943T3 (en) | Crystallization of epidaunorubicin x HCI | |
IL286555A (en) | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | |
EP2423204A4 (en) | Thiazolidinone derivative | |
GB0908905D0 (en) | Pharmaceutical compounds | |
GB0918923D0 (en) | Aminothiazole derivatives | |
IL257014A (en) | A novel formulation of meloxicam | |
GB0904499D0 (en) | A set of parts | |
GB0918652D0 (en) | New types of locator devices | |
GB0920625D0 (en) | Ace of plugs | |
GB0915125D0 (en) | Pharmaceutical compounds | |
GB0911699D0 (en) | Pharmaceutical compounds | |
GB0915678D0 (en) | Pharmaceutical compounds | |
GB0916458D0 (en) | Pharmaceutical compounds |